ReviewMetabolites2022

A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies.

Jelena Vekic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.